GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Cyp3a9 | affects response to substance | ISO | CYP3A5 (Homo sapiens) | 6480464 | CTD | CYP3A5 gene polymorphism affects the susceptibility to Ketoconazole | PMID:31102695 | Cyp3a9 | decreases activity | ISO | CYP3A5 (Homo sapiens) | 6480464 | CTD | Ketoconazole results in decreased activity of CYP3A5 protein | PMID:15557344 PMID:26302866 PMID:37788138 | Cyp3a9 | multiple interactions | ISO | CYP3A5 (Homo sapiens) | 6480464 | CTD | CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus]; Ketoconazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [CYP3A5 protein affects the metabolism of Alfentanil]; Ketoconazole inhibits the reaction [CYP3A5 protein results in increased hydroxylation of Testosterone]; Ketoconazole inhibits the reaction [CYP3A5 protein results in increased oxidation of Lithocholic Acid]; Ketoconazole inhibits the reaction [erdafitinib results in decreased activity of CYP3A5 protein]; Ketoconazole inhibits the reaction [flunisolide results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Fluticasone results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Triamcinolone Acetonide results in increased expression of CYP3A5 mRNA] | PMID:15731592 PMID:19384264 PMID:24555085 PMID:31102695 PMID:34189909 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |